Download PDF
Thromb Haemost 2015; 114(01): 11-13
DOI: 10.1160/TH15-02-0136
Current Controversies
Schattauer GmbH

The hazards of approximations and extrapolations: Insights from the ATLANTIC study

Gilles Montalescot
1   ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Pitié-Salpêtriėre, INSERM UMRS 1166, Paris, France
,
Arnoud W. van’t Hof
2   Department of Cardiology, Isala Clinics, Zwolle, the Netherlands
› Author Affiliations
Further Information

Publication History

Received: 12 February 2015

Accepted: 12 February 2015

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Editorial on Serebruany et al. Thromb Haemost 2015; 114: 7–8.

 

  • References

  • 1 Montalescot G, van’t Hof AW, Lapostolle F. et al. ATLANTIC Investigators.. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027.
    CrossrefPubMedGoogle Scholar
  • 2 Serebruany VL, Fortmann SD. Viewpoint: “under-utilisation of novel antiplatelet agents--myths, generics, and economics”. Thromb Haemost 2014; 112: 4-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Serebruany VL, Pokov AN, Fortmann SD. et al. Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: the cangrelor efficacy challenge. Thromb Haemost 2014; 111: 3-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Serebruany VL, DiNicolantonio JJ. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. Thromb Haemost 2013; 110: 5-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 The FDA ticagrelor Secondary Review.. Available for download at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220192.pdf
    PubMed
  • 6 Montalescot G, Bolognese L, Dudek D. et al. ACCOAST Investigators.. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.
    CrossrefPubMedGoogle Scholar
  • 7 Montalescot G, Collet JP, Ecollan P. et al AC-COAST Investigators.. Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI: The ACCOAST-PCI Study. J Am Coll Cardiol 2014; 64: 2563-2571.
    CrossrefPubMedGoogle Scholar
  • 8 DiNicolantonio JJ, Serebruany VL, Tomek A. Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning. Int J Cardiol 2013; 168: 1721-1723.
    CrossrefPubMedGoogle Scholar
  • 9 Cannon CP, Harrington RA, James S. et al. PLATelet inhibition and patient Outcomes Investigators.. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010; 375: 283-293.
    CrossrefPubMedGoogle Scholar
  • 10 Parodi G, Bellandi B, Xanthopoulou I. et al. Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circ Cardiovasc Interv 2014; 08: pii-e001593.
    PubMedGoogle Scholar